Hepatitis C Virus Antibodies in Outpatients with Chronic Kidney Disease

Overview

Journal Clin Exp Hepatol

Specialty Gastroenterology

Date 2019 Jan 4

PMID 30603675

Authors

Lubomir Skladany

Daniela Jancekova

Juraj Svac

Affiliations

Soon will be listed here.

Abstract

Aim Of The Study: To determine the seroprevalence of hepatitis C virus (HCV) in outpatients with chronic kidney disease (CKD) attending a nephrology clinic.

Material And Methods: Prospective observational study on consecutive outpatients attending a nephrology clinic. Inclusion criteria were age > 18 years, CKD, informed consent. There were no exclusion criterias. Recorded variables were age, gender, CKD grade and etiology, anti-HCV antibodies (Ab). Patients with positive HCV Abs were tracked for HCV RNA detection. Study interval was from November 2015 to March 2016. The study has been approved by the Ethic committee of F.D. Roosevelt University Hospital. Funded by Restricted Grant of AbbVie Slovakia.

Results: One hundred and thirty-four patients were enrolled, with median age 70 years (19.7-91), 52% women. CKD grades: G1/2 - 52 patients (39%), G3a - 34 patients (25%), G3b - 32 patients (24%), G4 - 8 patients (6%), G5 - 8 patients (6%); CKD etiology: tubulointerstitial nephritis (TIN) - 53 patients (40%), nephrosclerosis (NS) - 30 patients (22%), diabetic nephropathy (DN) - 23 patients (17%), glomerulonephritis (GN) - 23 patients (17%), others - 5 patients (4%). Anti-HCV antibodies were detected in 8 patients (6%). There were no significant differences in CKD grades between HCV+ and HCV- patients; Heymann nephritis and GN were significantly more frequent in HCV- patients, as was male gender. Of 8 HCV Ab positive patients, 5 were available for HCV RNA testing (2 died after completion of the study, 1 was lost to follow-up); of them, 1 patient tested positive.

Conclusions: Prevalence of anti-HCV antibodies in CKD patients was 6%, which is 4 times higher than in the general population of Slovakia; HCV RNA was detected in 1 patient (12.5%) of anti-HCV positive patients. Based on this result, multicentric, a larger-scale study is considered to be warranted.

References

Jadoul M, Poignet J, Geddes C, Locatelli F, Medin C, Krajewska M . The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004; 19(4):904-9. DOI: 10.1093/ndt/gfh012. View

Finelli L, Miller J, Tokars J, Alter M, Arduino M . National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005; 18(1):52-61. DOI: 10.1111/j.1525-139X.2005.18108.x. View

Tsui J, Vittinghoff E, Shlipak M, OHare A . Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2006; 17(4):1168-74. DOI: 10.1681/ASN.2005091006. View

Tsui J, Vittinghoff E, Shlipak M, Bertenthal D, Inadomi J, Rodriguez R . Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007; 167(12):1271-6. DOI: 10.1001/archinte.167.12.1271. View

Schreter I, Kristian P, Klement C, Kohutova D, Jarcuska P, Madarova L . [Prevalence of hepatitis C virus infection in Slovakia]. Klin Mikrobiol Infekc Lek. 2007; 13(2):54-8. View

. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008; (109):S1-99. DOI: 10.1038/ki.2008.81. View

Jia-Jung Lee , Lin M, Yang Y, Lu S, Chen H, Hwang S . Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis. 2010; 56(1):23-31. DOI: 10.1053/j.ajkd.2010.01.015. View

Patel P, Thompson N, Kallen A, Arduino M . Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis. 2010; 56(2):371-8. DOI: 10.1053/j.ajkd.2010.01.025. View

Chacko E, Surrun S, Mubarack Sani T, Pappachan J . Chronic viral hepatitis and chronic kidney disease. Postgrad Med J. 2010; 86(1018):486-92. DOI: 10.1136/pgmj.2009.092775. View

10.

Fabrizi F, Martin P, Dixit V, Messa P . Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012; 7(4):549-57. PMC: 3315338. DOI: 10.2215/CJN.06920711. View

11.

Latt N, Alachkar N, Gurakar A . Hepatitis C virus and its renal manifestations: a review and update. Gastroenterol Hepatol (N Y). 2013; 8(7):434-45. PMC: 3533219. View

12.

Chen Y, Lin H, Li C, Lee M, Su Y . A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int. 2013; 85(5):1200-7. DOI: 10.1038/ki.2013.455. View

13.

Fabrizi F . Hepatitis C virus, cryoglobulinemia, and kidney: novel evidence. Scientifica (Cairo). 2013; 2012:128382. PMC: 3820459. DOI: 10.6064/2012/128382. View

14.

Levin A, Stevens P . Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2013; 85(1):49-61. DOI: 10.1038/ki.2013.444. View

15.

Li W, Lee Y, Chen I, Wang S, Hsiao C, Loke S . Age and gender differences in the relationship between hepatitis C infection and all stages of Chronic kidney disease. J Viral Hepat. 2013; 21(10):706-15. DOI: 10.1111/jvh.12199. View

16.

Gragnani L, Fognani E, Piluso A, Zignego A . Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame?. World J Gastroenterol. 2014; 19(47):8910-5. PMC: 3870543. DOI: 10.3748/wjg.v19.i47.8910. View

17.

Sperl J, Frankova S, Senkerikova R, Neroldova M, Hejda V, Volfova M . Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection. World J Gastroenterol. 2015; 21(18):5496-504. PMC: 4427671. DOI: 10.3748/wjg.v21.i18.5496. View

18.

Fabrizi F, Verdesca S, Messa P, Martin P . Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2015; 60(12):3801-13. DOI: 10.1007/s10620-015-3801-y. View

19.

Fabrizi F, Martin P, Messa P . New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int. 2016; 89(5):988-994. DOI: 10.1016/j.kint.2016.01.011. View

20.

Omata M, Kanda T, Wei L, Yu M, Chuang W, Ibrahim A . APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016; 10(5):681-701. PMC: 5003900. DOI: 10.1007/s12072-016-9736-3. View